Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionLPL Financial LLC
Latest Disclosed Ownership268,062 shares
Latest Disclosed Value $ 119,700,571
LPL Financial LLC ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 6, 2026 - LPL Financial LLC filed a 13F-HR form disclosing ownership of 268,062 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $119,700,405 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 276,878 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -3.18% during the quarter. The current value of the position is $119,778,143 USD.

LPL Financial LLC has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 268,062 -8,816 -3.18 119,701 -4.64 0.0318
2026-02-11 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 276,878 12,696 4.81 125,525 21.32 0.0343
2025-11-12 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 264,182 23,566 9.79 103,464 -3.41 0.0302
2025-08-12 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 240,616 23,672 10.91 107,122 1.85 0.0357
2025-05-07 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 216,944 25,891 13.55 105,179 36.71 0.0409
2025-02-11 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 191,053 1,340 0.71 76,937 -12.80 0.0313
2024-11-08 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 189,713 -20,126 -9.59 88,232 -10.29 0.0393
2024-08-07 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 209,839 26,468 14.43 98,356 28.32 0.0490
2024-05-10 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 183,371 19,735 12.06 76,651 15.12 0.0412
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 163,636 -10,101 -5.81 66,582 10.21 0.0403
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 173,737 1,709 0.99 60,415 -0.20 0.0423
2023-07-31 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 172,028 4,528 2.70 60,538 14.71 0.0433
2023-05-10 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 167,500 2,161 1.31 52,774 10.53 0.0411
2023-02-07 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 165,339 32,264 24.24 47,746 23.92 0.0409
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 133,075 -2,741 -2.02 38,530 0.68 0.0372
2022-08-12 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 135,816 -688 -0.50 38,271 7.43 0.0364
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 136,504 16,002 13.28 35,623 34.62 0.0306
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 120,502 7,919 7.03 26,462 29.58 0.0222
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 112,583 39,081 53.17 20,421 37.79 0.0192
2021-08-13 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 73,502 10,071 15.88 14,820 8.72 0.0150
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 63,431 20,735 48.56 13,631 35.08 0.0157
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 42,696 -2,219 -4.94 10,091 -17.44 0.0131
2020-11-09 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 44,915 823 1.87 12,222 -4.52 0.0191
2020-08-13 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 44,092 3,864 9.61 12,800 33.72 0.0223
2020-05-14 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 40,228 2,839 7.59 9,572 16.93 0.0206
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 37,389 1,068 2.94 8,186 33.02 0.0149
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 36,321 -3,953 -9.82 6,154 -16.67 0.0125
2019-08-09 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 40,274 -2,810 -6.52 7,385 -6.81 0.0157
2019-05-08 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,084 -397 -0.91 7,925 9.99 0.0180
2019-02-07 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,481 -765 -1.73 7,205 -15.51 0.0192
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 44,246 3,126 7.60 8,528 22.02 0.0204
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 41,120 2,040 5.22 6,989 9.73 0.0183
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 39,080 -3,946 -9.17 6,369 -1.23 0.0175
2018-02-14 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,026 5,887 15.85 6,448 14.18 0.0196
2017-11-14 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 37,139 23,396 170.24 5,647 218.86 0.0199
2017-08-14 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,743 3,641 36.04 1,771 63.23 0.0067
2017-05-15 2017-03-31 13F VERTEX PHARM COM 92532F100 10,102 -3,320 -24.74 1,085 7.96 0.0074
2017-02-13 2016-12-31 13F VERTEX PHARM COM 92532F100 13,422 -3,470 -20.54 1,005 -31.16 0.0076
2016-11-16 2016-09-30 13F VERTEX PHARM COM 92532F100 16,892 -712 -4.04 1,460 -7.48 0.0139
2016-08-15 2016-06-30 13F VERTEX PHARM COM 92532F100 17,604 9,156 108.38 1,578 121.94 0.0133
2016-05-16 2016-03-31 13F VERTEX PHARM COM 92532F100 8,448 468 5.86 711 -27.82 0.0020
2016-02-12 2015-12-31 13F VERTEX PHARM COM 92532F100 7,980 -5,338 -40.08 985 -35.41 0.0027
2015-11-13 2015-09-30 13F VERTEX PHARM COM 92532F100 13,318 1,125 9.23 1,525 -2.93 0.0084
2015-08-14 2015-06-30 13F VERTEX PHARM COM 92532F100 12,193 734 6.41 1,571 17.77 0.0080
2015-05-14 2015-03-31 13F VERTEX PHARM COM 92532F100 11,459 3,656 46.85 1,334 43.91 0.0068
2015-02-13 2014-12-31 13F VERTEX PHARM COM 92532F100 7,803 935 13.61 927 25.78 0.0051
2014-11-10 2014-09-30 13F VERTEX PHARM COM 92532F100 6,868 3,254 90.04 737 115.50 0.0044
2014-08-05 2014-06-30 13F/A-1 VERTEX PHARM COM 92532F100 3,614 474 15.10 342 54.05 0.0020
2014-08-05 2014-06-30 13F VERTEX PHARM COM 92532F100 3,614 1,693
2014-05-12 2014-03-31 13F VERTEX PHARM COM 92532F100 3,140 448 16.64 222 11.00 0.0014
2014-02-13 2013-12-31 13F VERTEX PHARM COM 92532F100 2,692 -10,681 -79.87 200 -79.72 0.0012
2013-11-04 2013-09-30 13F VERTEX PHARM COM 92532F100 13,373 -9,971 -42.71 986 -47.24 0.0066
2013-08-15 2013-06-30 13F VERTEX PHARM COM 92532F100 23,344 23,344 1,869 0.0134
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-08-12 2025-06-30 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-05-07 2025-03-31 13F VERTEX PHARMACEUTICALS COM Call 500 242 n/a n/a n/a
2024-05-10 2024-03-31 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM Call 3,000 1,221 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.